Table 1.
Characteristics of 53 Mexican pediatric kidney transplant recipients
| Mean | SD | Median | Range | |
|---|---|---|---|---|
| Gender [male/female* (n)] | 34/19 | |||
| Age (years) | 14.6 | 3.2 | 16 | 2–19 |
| Body weight (kg) | 48.2 | 15.2 | 48 | 11.2–75.5 |
| Height (cm) | 149 | 17.8 | 153 | 81–170 |
| BSA (m2) | 1.4 | 0.3 | 1.4 | 0.5–1.9 |
| Crs (mg dl–1) | 1.1 | 0.4 | 1.1 | 0.4–2.6 |
| Hb (g dl–1) | 12.9 | 1.7 | 13.3 | 8.5–17 |
| Hct (%) | 38.4 | 5 | 39.3 | 24.2–49.1 |
| AST (U l–1) | 21.4 | 8.1 | 20 | 7–46 |
| ALT (U l–1) | 38 | 13.4 | 35 | 22–103 |
| STP (g dl–1) | 7.2 | 1.2 | 7.3 | 0.17–8.7 |
| Alb (g dl–1) | 4.2 | 0.7 | 4.3 | 0.49–5.1 |
| Post-operative days (days) | 391.6 | 327.2 | 244 | 50–1230 |
| Tacrolimus total dose (mg) | 2.3 | 1.3 | 2 | 0.5–6 |
| Tacrolimus weighted dose (mg kg–1) | 0.054 | 0.043 | 0.047 | 0.009–0.268 |
| Prednisone dose† (mg day–1) | 6.7 | 2.2 | 7.5 | 2–12.5 |
| Verapamil dose† (mg day–1) | 184.5 | 94.8 | 170 | 37.5–360 |
| CYP3A5 genotype* (n) | ||||
| *1/*1 | 3 | |||
| *1/*3 | 21 | |||
| *3/*3 | 29 | |||
| ABCB1 genotype* | ||||
| 1236C > T (n) | ||||
| C/C | 16 | |||
| C/T | 18 | |||
| T/T | 19 | |||
| 2677G > T/A (n) | ||||
| G/G | 18 | |||
| G/T† | 19 | |||
| T/T§ | 16 | |||
| 3435C > T (n) | ||||
| C/C | 13 | |||
| C/T | 22 | |||
| T/T | 18 |
*
For non-continuous covariates, values were the number of patients for each category (n).
†
Only some patients were receiving this drug.
‡
Includes patients with genotype G/A.
§
Includes patients with genotype T/A.
Alb, serum albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; Crs, serum creatinine; Hb, haemoglobin; Hct, haematocrit; STP, serum total protein.